Compare Jumia Technologies AG - ADR (JMIA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs TG Therapeutics Inc — how do they compare? Jumia Technologies AG - ADR trades at $6.35 (market cap $783.99M), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: TG Therapeutics Inc is far larger — about 10.5× Jumia Technologies AG - ADR's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| JMIA | TGTX | |
|---|---|---|
Market Cap | $783.99M | $8.26B |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $59.06 |
52-Week Low | $4.45 | $26.39 |
Enterprise Value | $731.09M | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Jumia Technologies (JMIA) trades at $6.28, down 3.38% on the day, as the stock faces bearish technical pressure despite positive analyst sentiment. The company shows improving fundamentals with revenue growth to $188.93M in 2025 and narrowing losses, though it remains unprofitable with a -30.79% net margin. Recent Q1 2026 results showed 39% revenue growth and progress toward the 2027 profitability target, supported by strategic initiatives including upcountry expansion and the Starlink partnership.
While analyst consensus is strongly bullish (71% buy ratings), JMIA faces significant execution risks in achieving profitability amid African market challenges. The stock's current valuation at 3.86x sales appears reasonable for the growth trajectory, but persistent losses and high P/B ratio of 59.97 warrant caution. Near-term catalysts include continued GMV growth and margin improvement, but investors should monitor cash burn and competitive pressures.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
